Physician profile
Jayesh S Shah
NPI 1366556771
$597.43
in general payments reported to CMS, 2019-2025
12 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $35.85 · 2023: $176 · 2024: $24.61 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.39 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $193.51 | 2019-2025 | |
| Outset Medical INC | $125.33 | 2023 | |
| Vifor Pharma, INC. | $59.31 | 2019-2023 | Veltassa |
| Amgen INC. | $54.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.61 | 2019 | |
| Akebia Therapeutics INC | $43.96 | 2020-2024 | Vafseo |
| Fresenius USA Marketing, INC. | $27.83 | 2019 | |
| Mallinckrodt Hospital Products INC. | $25.76 | 2023 | Terlivaz |
| Bard Peripheral Vascular, INC. | $16.50 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayesh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.